AUSTIN, Texas–(BUSINESS WIRE)–Texas Original, Texas’ leading medical cannabis provider, announced its first product specifically designed to help qualifying patients who suffer from insomnia, night terrors or restlessness as a result of various medical conditions. The Sweet Dreams sleep gummy will be available to the company’s state-leading patient network in October. Sweet Dreams is the first … [Read more…]
ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc. (NASDAQ: NAOV) (“Nano” or the “Company”), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, … [Read more…]
Participating facilities nationwide can now offer members free, 24/7 access to licensed counselors via a confidential, text-based platform NEW YORK–(BUSINESS WIRE)–#counslr—Counslr, a platform providing unlimited access to text-based mental health support via mobile app with licensed counselors, announced today it is now expanding its support to all 50 states. Now, higher education institutions, companies, healthcare … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Single-use Bioprocessing Sensors & Probes Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Single-use Bioprocessing Sensors & Probes Market is projected to reach USD 1,773.39 million by 2027 from USD 862.02 million in 2021, at a CAGR 12.77% during the forecast period. Market Statistics: … [Read more…]
Submits Revised Requisition for General Meeting of Shareholders Condemns Company’s Governance and Corrects the Record on Mereo’s Misleading Public Statements NEW YORK–(BUSINESS WIRE)–Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), today issued … [Read more…]
Featuring BIPOC youth storytellers from around the globe, climate change-focused podcast now available through YR Media and Critical Frequency across all major platforms OAKLAND, Calif.–(BUSINESS WIRE)–#YRMedia—Inherited, the widely acclaimed youth climate movement storytelling podcast, is back for an all-new season, featuring a fresh lineup of powerful and personal stories from young people, particularly from historically … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. today announced that the donated clinical data from the placebo arm of the CENTAUR clinical trial that evaluated the safety, efficacy, and survival benefits of AMX0035 in adult participants with amyotrophic lateral sclerosis (ALS) are now available in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. The PRO-ACT project … [Read more…]
Achievers and Quest Diagnostics secure the Gold award for Best Advance in Employee Recognition Program in the Talent Management category TORONTO–(BUSINESS WIRE)–#EmployeeExperience–Achievers, an industry-leading employee experience software platform, announces its joint win of a Gold award by Brandon Hall Group with its customer case study of Quest Diagnostics (NYSE: DGX), the world’s leading provider of … [Read more…]
Value-based care is here to stay; the Veradigm Network is at the forefront of supporting healthcare providers to improve patient outcomes today and in the future CHICAGO–(BUSINESS WIRE)–$MDRX #healthIT–Veradigm®, a leading provider of healthcare data and technology solutions and a business unit of Allscripts Healthcare Solutions (NASDAQ: MDRX), and Vytalize Health, a new kind of … [Read more…]
Dry Eye Disease NDA for Reproxalap Expected to be Submitted in the Fourth Quarter of 2022 Pre-NDA Meeting for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma Scheduled for the Fourth Quarter of 2022 Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Expected in the Third or Fourth … [Read more…]
